Severe Kawasaki disease in a 3-month-old patient: a case report

BMC Research Notes

Mario La Rosa¹  Pietro Sciacca¹  Valeria Di Stefano¹  Giuseppe Fabio Parisi¹  Giacomo Gravina¹  Patrizia Barone¹  Salvatore Leonardi¹ 

[1] Unit of Broncho-Pneumology and Cystic Fibrosis, Department of Medical and Pediatric Science, University of Catania, Via Santa Sofia 78, Catania 95123, Italy

关键词: Therapy;    Coronary artery aneurysms;    Infant;    Kawasaki disease;   

Others  :  1140631
DOI  :  10.1186/1756-0500-6-500

 received in 2013-06-11, accepted in 2013-11-26,  发布年份 2013

【 摘 要 】

Background

Kawasaki disease is a multi-system vasculitis which usually occurs in children under 5 years of age. In infants under three months of age, it is very rare and usually associated with a high incidence of incomplete or atypical forms, often unresponsive to treatment. This condition increases the risk of cardiovascular complications such as coronary artery aneurysms.

Case presentation

We describe a 3-month-old infant who developed early and severe aneurysms in three coronary arteries despite a timely administration of intravenous immunoglobulins, followed by three days of intravenous methylprednisolone.

Conclusion

This case report underlines that the development of coronary artery aneurysm correlates with a delayed diagnosis and treatment, incomplete or atypical forms of the disease, and additionally the severity of clinical presentation, especially in cases of very young infants below 3 months of age. Our case is notable because of the very young age of the patient, the severity of clinical presentation with an early development of coronary artery aneurysms and the unresponsiveness to the therapy.

【 授权许可】

   
2013 Leonardi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, McCluskey RT, Sinico RA, Rees AJ, Van Es LA, Waldherr R, Wiik A: Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994, 37(2):187-192.
• [2]Taubert K, Rowley A, Shulman S: Seven-year national survey of Kawasaki disease and rheumatic fever. Pediatr Infect Dis J 1994, 13:704-708.
• [3]Falcini F, Capannini S, Rigante D: Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J 2011, 20:9-17.
• [4]Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967, 16:178.
• [5]Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H: Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995, 95:475-479.
• [6]Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA: Committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American heart association: diagnosis, treatment, and long-term management in Kawasaki disease: a statement for health professionals from the committee on reumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Pediatrics 2004, 114:1708-1733.
• [7]Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A: Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113:2606-2612.
• [8]Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T: Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006, 149:237-240.
• [9]Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J: Predition of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007, 166:131-137.
• [10]Taubert KA, Rowley AH, Shulman ST: Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991, 119:279-282.
• [11]Harada K, Yamaguchi H, Kato H, Nishibayashi Y, Ichiro S, Okazaki T, Sato Y, Furusho K, Okawa S, Kawasaki T: Indication for intravenous gamma globulin treatment for Kawasaki disease. In Proceedings of the Fourth International Symposium on Kawasaki Disease. Edited by Takahashi M, Taubert K. Dallas, Tex: American Heart Association; 1993:459-462.
• [12]Beiser AS, Takahasha M, Baker AL, Sundel RP, Newburger JW, United States Multicenter Kawasaki Disease Study Group: A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998, 81:1116-1120.
• [13]Forsey J, Mertens L: Atypical Kawasaki disease—a clinical challenge. Eur J Pediatr 2012, 171(4):609-611. Epub 2011 Nov 25
• [14]Marchesi A, Pongiglione G, Rimini A, Longhi R, Villani A: Malattia di Kawasaki: Linee Guida italiane. Prospettive in Pediatria 2008, 38:266-283.
• [15]Rowley AH, Shulman ST: Kawasaki Syndrome. Clin Microbiol Rev 1998, 11(3):405-414.
• [16]Cabral M, Correia P, Brito MJ, Conde M, Carreiro H: Kawasaki disease in a young infant: diagnostic challenges. Acta Reumatol Port 2011, 36(3):304-308.
• [17]Tsuchida S, Yamanaka T, Yanagawa H: Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Pediatr 1996, 39:387-391.
• [18]Leonardi S, Miraglia del Giudice M, La Rosa M, Bellanti J: Atopic disease, immune system and environment. Alllergy Asthma Proc 2007, 28:410-417.
• [19]Onoyama S, Ihara K, Yamaguchi Y, Ikeda K, Yamaguchi K, Yamamura K, Hoshina T, Mizuno Y, Hara T: Genetic susceptibility to kawasaky disease: analysis of pattern recognition receptor genes. Hum Immunol 2012, 73:654-660.
• [20]Nakamura Y, Yashiro M, Uehara R, Sadakane A, Tsuboi S, Aoyama Y, Kotani K, Tsogzolbaatar EO, Yanagawa H: Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012, 22(3):216-221.
• [21]Ikeda K, Yamaguchi K, Tanaka T, Mizuno Y, Hijikata A, Ohara O, Takada H, Kusuhara K, Hara T: Unique activation status of peripheral blood monocuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol 2010, 160:246-255.
• [22]Chuang CH, Hsiao MH, Lin TY: Kawasaki disease in infants three months of age or younger. J Microbiol Immunol Infect 2006, 39(5):387-391.
• [23]Burns JC, Wiggins JW Jr, Toews WH, Newburger JW, Leung DY, Wilson H, Glode MP: Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986, 109:759-763.
• [24]Pannaraj PS, Turner CL, Bastian JF, Burns JC: Failure to diagnose Kawasaki disease at the extremes of the pediatric age range. Pediatr Infect Dis J 2004, 23(8):789-791.
• [25]Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T, Osaka Kawasaki Disease Study Group: Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009, 168(2):181-185. Epub 2008 Apr 30
• [26]Hashino K, Ishii M, Iemura M, Akagi T, Kato H: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211-217.
• [27]Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M: Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics 2012, 129(1):e17-e23. Epub 2011 Dec 5
• [28]Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S: Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol 2012, 39:864-867.